Pooled human platelet lysate: a viable alternative to FBS for 2D and 3D culture of mesenchymal stem cells
Available to view on demand. Stemulateâ„¢ Pooled Human Platelet Lysate provides potential advantages over fetal bovine serum for the expansion of mesenchymal stem cells in 2D and 3D culture systems.
The use of fetal bovine serum is likely to limit the scalability and
cost-effectiveness of human mesenchymal stem cell manufacturing and
therefore must be addressed. Stemulate
(Pooled Human Platelet Lysate) has been proposed as a viable
alternative due to several potentially advantageous characteristics
during culture. This webinar will review the growth kinetics,
characterization, estimated cost per dose and process transfer from
monolayer to microcarrier culture of bone marrow and adipose-derived
MSCs in FBS and Stemulate
What will you learn?
- Limitations of fetal bovine serum as a cell culture supplement
- Human viable alternative to fetal bovine serum
- How StemulateTM Pooled Human Platelet Lysate performs in HMSC and ADSC cultures
- Advantages and savings related to using human platelet lysate (StemulateTM)
Who may this interest?
- Anyone interested in alternatives to fetal bovine serum for cell culture media supplementation
- Anyone interested in reducing the cost of mesenchymal stem cell manufacturing
- Anyone interested in moving from 2D/monolayer cell culture to 3D/microcarrier culture
Tom graduated with a master’s degree in Chemical Engineering from
the University of Bath (UK) which included a yearlong internship as a
process engineer in the research and development division at BP
Chemicals in the UK. Following this, he went on to complete his PhD
(sponsored by FUJIFILM Diosynth Biotechnologies) at Loughborough
University as part of the Doctoral Training Centre in Regenerative
Medicine. His PhD focuses on developing a process control strategy for
the large-scale manufacture of adherent stem cells and has published a
number of research papers and book chapters on stem cell manufacturing.
He is currently working as a business development associate at PCT (a
Caladrius Company) in New Jersey, USA.
Director, Advanced Laboratory Products
Brad King is the Director of Advanced Laboratory Products for
Cook Regentec. The Laboratory Products Group provides tools to enable
basic and clinical research in regenerative medicine, including
TM Pooled Human Platelet Lysate and CellSeal Closed-system Cryogenic Vals.
Global Product Manager, CellSeal
Evonne R Fearnot holds a master’s degree in Biomedical
Engineering from Purdue University, and two undergraduate degrees in
Mechanical Engineering and Psychology, both from Cedarville University.
Beginning in 2012, Evonne was employed by a Cook company (Cook General
BioTechnology, LLC), with the responsibility for validation testing, and
drafting domestic and international regulatory documents involving
medical device containers for biological/cell-based products. Evonne
presently holds a position at Cook General BioTechnology, LLC, as Global
Product Manager, responsible for providing focus, guidance and
long-term brand vision for the business unit and their products.
Director, Medical Affairs
Dr Henk Snyman is currently the Global Director of Medical
Affairs for Cook Regentec, a subsidiary of Cook Medical, exclusively
focused on Regenerative Medicine. He has over 20 years of clinical
research and management experience in high-tech medical industries.
Prior experiences include starting up the European headquarters for a
molecular toxicology company, managing the European division for a
cancer screening and instrumentation company, as well as leading
biopharmaceutical subsidiaries with development laboratories. For the
last 8 years he has been involved with adult stem cells, notably
mesenchymal stem cells from adipose and BM tissue. Dr Snyman received
his MD in South Africa and is a Fellow of the Royal College of Surgeons
in the UK.
Chris Taylor holds a Biomedical Engineering degree from the
Purdue School of Engineering. He has been an employee of Cook Regentec
for 3 years. Subject matter expert on Developed Cook Regentec’s
protocols and procedures for the manufacture of Stemulate
Business Development Manager for Cell Therapy, Northern Europe
Steven Thompson has a research background in regenerative medicine,
obtaining his PhD from the University of Liverpool in Stem Cells and
Regenerative Medicine. He previously gained gene editing and RNAi
experience with a leading life science company prior to undertaking his
current role of Business Development Manager for Cell Therapy at Cook
Regentec, where he is responsible for identifying and addressing
problems related to regenerative medicine strategies.
Senior Vice President and Lead Scientist
Dr Woods co-founded General BioTechnology LLC (GBT) in 1997, an
R&D company devoted to advancing cell culture and cryopreservation
to facilitate mainstream clinical use of cellular therapeutics. Dr Woods
led the company from its inception through successful acquisition by
Cook Medical in 2012. In his years of service, he has held
administrative roles, ran a continuous research endeavor with numerous
scientific grants awarded through the U.S. Department of Defense, the
U.S. National Institutes of Health and the State of Indiana, and oversaw
clinical laboratory operations as a board certified High Complexity
Clinical Laboratory Director (HCLD). With GBT now fully integrated into
Cook Regentec, Dr Woods focuses on innovation and early stage
For a full list of other webinars available on RegMedNet please see here.